JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

Search

Editas Medicine Inc

Fermé

SecteurSoins de santé

2.99 -2.29

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.93

Max

3.06

Chiffres clés

By Trading Economics

Revenu

23M

-53M

Ventes

-1.1M

3.6M

Marge bénéficiaire

-1,487.842

Employés

246

EBITDA

23M

-49M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+27.63% upside

Dividendes

By Dow Jones

Prochains Résultats

3 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

108M

292M

Ouverture précédente

5.28

Clôture précédente

2.99

Sentiment de l'Actualité

By Acuity

50%

50%

168 / 373 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Editas Medicine Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

30 oct. 2025, 23:32 UTC

Actions en Tendance

Stocks to Watch: Amazon, Reddit, SPS Commerce

30 oct. 2025, 23:02 UTC

Résultats

AIA Group 3Q Value of New Business Grew

30 oct. 2025, 23:45 UTC

Market Talk

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

30 oct. 2025, 23:00 UTC

Résultats

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

30 oct. 2025, 22:59 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Equities Roundup: Market Talk

30 oct. 2025, 22:59 UTC

Market Talk
Acquisitions, Fusions, Rachats

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

30 oct. 2025, 22:56 UTC

Market Talk

Australia Shares Shaping to Pare Recent Losses -- Market Talk

30 oct. 2025, 22:35 UTC

Résultats

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

30 oct. 2025, 22:35 UTC

Résultats

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

30 oct. 2025, 22:31 UTC

Résultats

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

30 oct. 2025, 22:29 UTC

Résultats

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

30 oct. 2025, 22:27 UTC

Résultats

Minas Buenaventura 3Q EPS 66c >BVN

30 oct. 2025, 22:27 UTC

Résultats

Minas Buenaventura 3Q Rev $431M >BVN

30 oct. 2025, 22:27 UTC

Résultats

Minas Buenaventura 3Q Net $179M >BVN

30 oct. 2025, 22:16 UTC

Market Talk
Résultats

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

30 oct. 2025, 22:14 UTC

Résultats

Review & Preview: A Tech Earnings Storm -- Barrons.com

30 oct. 2025, 22:00 UTC

Résultats
Acquisitions, Fusions, Rachats

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

30 oct. 2025, 21:39 UTC

Résultats

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 oct. 2025, 21:26 UTC

Résultats

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 oct. 2025, 21:14 UTC

Market Talk
Résultats

Apple Sees Record Quarterly Services Revenue -- Market Talk

30 oct. 2025, 21:09 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

30 oct. 2025, 21:09 UTC

Market Talk
Résultats

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

30 oct. 2025, 21:04 UTC

Résultats

Apple Expects Big December Quarter on iPhone Upgrades -- Update

30 oct. 2025, 21:03 UTC

Résultats

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

30 oct. 2025, 21:03 UTC

Résultats

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

30 oct. 2025, 21:00 UTC

Résultats

Eldorado Gold Skouries on Track for 1Q of 2026

30 oct. 2025, 21:00 UTC

Résultats

Eldorado Gold 3Q Adj EPS 41c >EGO

30 oct. 2025, 21:00 UTC

Résultats

Eldorado Gold 3Q Rev $434.7M >EGO

30 oct. 2025, 21:00 UTC

Résultats

Eldorado Gold 3Q Net $56M >EGO

30 oct. 2025, 21:00 UTC

Résultats

Eldorado Gold 3Q EPS 27c >EGO

Comparaison

Variation de prix

Editas Medicine Inc prévision

Objectif de Prix

By TipRanks

27.63% hausse

Prévisions sur 12 Mois

Moyen 3.88 USD  27.63%

Haut 6 USD

Bas 1 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

12 ratings

5

Achat

5

Maintien

2

Vente

Score Technique

By Trading Central

1.33 / 1.54Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Neutral Evidence

Long Terme

No Evidence

Sentiment

By Acuity

168 / 373Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
help-icon Live chat